Evaluating the impact M&As will have on your outsourcing strategy - Clinical Trials Arena

Go back

Evaluating the impact M&As will have on your outsourcing strategy

Related Content

Kisunla™ (donanemab-azbt)

Project

Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer's Disease, US

Modeyso

Project

Modeyso (dordaviprone) for the Treatment of Diffuse Midline Glioma, US

Featured-Image-Nucala-mepolizumab

Project

Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES), UK

Jascayd

Project

Jascayd (nerandomilast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF), US

Briumvi

Project

Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, US

EKTERLY (sebetralstat) for the Treatment of Hereditary Angioedema, USA

Project

EKTERLY (sebetralstat) for the Treatment of Hereditary Angioedema, USA

IBTROZI (taletrectinib) for the Treatment of Non-small Cell Lung Cancer, USA

Project

IBTROZI for the Treatment of Non-small Cell Lung Cancer, US

Breyanzi (lisocabtagene maraleucel) for the Treatment of Large B-cell lymphoma (LBCL)

Project

Breyanzi for the Treatment of Large B-cell Lymphoma, US

FORZINITY (elamipretide) for Muscle Strength in Barth Syndrome, USA

Project

FORZINITY (elamipretide) for Muscle Strength in Barth syndrome, USA

HERNEXEOS® (zongertinib tablets) for the Treatment of HER-2 Mutant Advanced NSCLC, USA

Project

HERNEXEOS (zongertinib tablets) for the Treatment of HER-2 Mutant Advanced NSCLC, USA